CoChat

Biological basis for novel mesothelioma therapies

Open access

The DOI matches its Crossref record; 224 of the 228 references it cites were found in a registry or an index.

Abstract

Mesothelioma is an aggressive cancer that is associated with exposure to asbestos. Although asbestos is banned in several countries, including the UK, an epidemic of mesothelioma is predicted to affect middle-income countries during this century owing to their heavy consumption of asbestos. The prognosis for patients with mesothelioma is poor, reflecting a failure of conventional chemotherapy that has ultimately resulted from an inadequate understanding of its biology. However, recent work has revolutionised the study of mesothelioma, identifying genetic and pathophysiological vulnerabilities, including the loss of tumour suppressors, epigenetic dysregulation and susceptibility to nutrient stress. We discuss how this knowledge, combined with advances in immunotherapy, is enabling the development of novel targeted therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-021-01462-2

Cites

224 of 224 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The histopathological classification of malignant mesothelioma. Images of haematoxylin and eosin (H&E) stained normal pleura (×100), epithelioid (×100), sarcomatoid (×100) and biphasic (×100) mesothelioma subtypes, indicating the presence of flat, cuboidal cells in epithelioid mesothelioma as well as spindle cells and abundant stroma in sarcomatoid mesothelioma. Scale bar = 200 µm. The images were provided by Royal Papworth Hospital Research Tissue Bank.
Fig. 1 The histopathological classification of malignant mesothelioma. Images of haematoxylin and eosin (H&E) stained normal pleura (×100), epithelioid (×100), sarcomatoid (×100) and biphasic (×100) mesothelioma subtypes, indicating the presence of flat, cuboidal cells in epithelioid mesothelioma as well as spindle cells and abundant stroma in sarcomatoid mesothelioma. Scale bar = 200 µm. The images were provided by Royal Papworth Hospital Research Tissue Bank.CC BY · PubMed Central
Fig. 2 Tumour suppressor functions of BAP1, Merlin and p16INK4a/p14ARF proteins. a In the endoplasmic reticulum (ER), BAP1 deubiquitinates and stabilises the type-3 inositol-1,4,5-trisphosphate receptor (IP3R3), controlling the Ca2+ flux into mitochondria and the subsequent release of cytochrome c and apoptosis. The nuclear BAP1 activity leads to BRCA1–BARD1-complex-dependent DNA repair as well as chromatin modification through histone deubiquitination. b At the plasma membrane, Merlin inhibits promigratory and prosurvival signalling cascades, including those mediated by focal adhesion kinase (FAK)–Src and phosphatidylinositol 3-kinase (PI3K)–AKT–mammalian target of rapamycin (mTOR)1 pathways. It also activates the mammalian Hippo pathway, which results in the phosphorylation of YAP/TAZ transcription co-activators, precluding their nuclear translocation and the TEA domain (TEAD)-dependent expression of numerous oncogenes. c p14ARF promotes cell-cycle arrest and apoptosis by preventing p53 degradation, while p16INK4a inhibits cell-cycle progression by binding and inactivating CDK4/6 protein and the downstream effector, retinoblastoma (Rb) protein.
Fig. 2 Tumour suppressor functions of BAP1, Merlin and p16INK4a/p14ARF proteins. a In the endoplasmic reticulum (ER), BAP1 deubiquitinates and stabilises the type-3 inositol-1,4,5-trisphosphate receptor (IP3R3), controlling the Ca2+ flux into mitochondria and the subsequent release of cytochrome c and apoptosis. The nuclear BAP1 activity leads to BRCA1–BARD1-complex-dependent DNA repair as well as chromatin modification through histone deubiquitination. b At the plasma membrane, Merlin inhibits promigratory and prosurvival signalling cascades, including those mediated by focal adhesion kinase (FAK)–Src and phosphatidylinositol 3-kinase (PI3K)–AKT–mammalian target of rapamycin (mTOR)1 pathways. It also activates the mammalian Hippo pathway, which results in the phosphorylation of YAP/TAZ transcription co-activators, precluding their nuclear translocation and the TEA domain (TEAD)-dependent expression of numerous oncogenes. c p14ARF promotes cell-cycle arrest and apoptosis by preventing p53 degradation, while p16INK4a inhibits cell-cycle progression by binding and inactivating CDK4/6 protein and the downstream effector, retinoblastoma (Rb) protein.CC BY · PubMed Central
Fig. 3 Therapeutic strategies in mesothelioma classified according to their mode of action. Immune checkpoint inhibitors block signalling that suppresses immune-cell activity, such as PD-1–PD-L1 and B7-1/2–CTLA-4 interactions, which is upregulated by tumour cells. Tumour-associated antigens (TAAs) can be targeted using monoclonal antibodies against proteins such as mesothelin, by vaccine therapy to stimulate the immune response and by using antibody–drug conjugates (ADCs) that target proteins such as mesothelin, 5TA, CD26 and CD30. Autologous dendritic cells pulsed with autologous or allogeneic tumour cell lysate act to prime host immunity, while chimeric antigen receptor CAR T cells contain chimaeric receptors that have been generated to specifically bind to TAAs on the cell surface. Other therapeutic approaches include oncolytic viruses that directly kill cancer cells by lysis or indirectly by stimulating immune response. They have been engineered to increase viral specificity (by introducing TAAs), cytotoxicity (by introducing e.g. pro-apoptotic or immunostimulatory genes), and monitoring (by introducing reporter genes).
Fig. 3 Therapeutic strategies in mesothelioma classified according to their mode of action. Immune checkpoint inhibitors block signalling that suppresses immune-cell activity, such as PD-1–PD-L1 and B7-1/2–CTLA-4 interactions, which is upregulated by tumour cells. Tumour-associated antigens (TAAs) can be targeted using monoclonal antibodies against proteins such as mesothelin, by vaccine therapy to stimulate the immune response and by using antibody–drug conjugates (ADCs) that target proteins such as mesothelin, 5TA, CD26 and CD30. Autologous dendritic cells pulsed with autologous or allogeneic tumour cell lysate act to prime host immunity, while chimeric antigen receptor CAR T cells contain chimaeric receptors that have been generated to specifically bind to TAAs on the cell surface. Other therapeutic approaches include oncolytic viruses that directly kill cancer cells by lysis or indirectly by stimulating immune response. They have been engineered to increase viral specificity (by introducing TAAs), cytotoxicity (by introducing e.g. pro-apoptotic or immunostimulatory genes), and monitoring (by introducing reporter genes).CC BY · PubMed Central
Fig. 4 Pleural anatomy. a Embryonic pleural development. (i) Representation of the trilaminar germ disc following gastrulation together with the amniotic cavity and definitive yolk sac. (ii) During gastrulation, the mesoderm layer forms and the lateral plate mesoderm subdivides into somatic and splanchnic mesoderm. (iii) Following lateral flexion, the intra-embryonic coelom is lined by somatic and splanchnic mesoderm. (iv) The pleuropericardial folds extend to the midline and fuse with the ventral surface of foregut mesoderm, forming the primitive pleural cavities. (v) The somatic and splanchnic mesoderm is lined by parietal and visceral pleura respectively, which are contiguous with each other at the level of the hilum. b Anatomy of the thorax showing the relationship between the lungs, thoracic ribcage and pleura. The pleural cavity is defined by the space between adjacent visceral and parietal pleura. The pleura can be subdivided into five layers: mesothelial cells, basal lamina, superficial elastic layer, connective tissue layer and the deep fibroelastic layer. The deep layer is tightly adhered to the underlying structures e.g. muscle, rib or lung parenchyme.
Fig. 4 Pleural anatomy. a Embryonic pleural development. (i) Representation of the trilaminar germ disc following gastrulation together with the amniotic cavity and definitive yolk sac. (ii) During gastrulation, the mesoderm layer forms and the lateral plate mesoderm subdivides into somatic and splanchnic mesoderm. (iii) Following lateral flexion, the intra-embryonic coelom is lined by somatic and splanchnic mesoderm. (iv) The pleuropericardial folds extend to the midline and fuse with the ventral surface of foregut mesoderm, forming the primitive pleural cavities. (v) The somatic and splanchnic mesoderm is lined by parietal and visceral pleura respectively, which are contiguous with each other at the level of the hilum. b Anatomy of the thorax showing the relationship between the lungs, thoracic ribcage and pleura. The pleural cavity is defined by the space between adjacent visceral and parietal pleura. The pleura can be subdivided into five layers: mesothelial cells, basal lamina, superficial elastic layer, connective tissue layer and the deep fibroelastic layer. The deep layer is tightly adhered to the underlying structures e.g. muscle, rib or lung parenchyme.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 224 references

Research works printed but not linked: 2

  1. Schramm A, Opitz I, Thies S, Seifert B, Moch H, Weder W, et al. Prognostic significance of epithelial–mesenchymal transition in malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2010;37:566–72. · DOI · Paper page
  2. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol. 1999;189:72–78. · doi:10.1002/(sici)1096-9896(199909)189:1<72::aid-path401>3.0.co;2-0

Cited by

See all 32

Metadata

Authors
Obacz, J., Yung, H., Shamseddin, M., Linnane, E., Liu, X., Azad, A. A., Rassl, D. M., Fairen-Jimenez, D., Rintoul, R. C., Nikolić, M. Z., & Marciniak, S. J.
Affiliations
  • University of Cambridge (GB)
  • University College London (GB)
  • Wellcome Sanger Institute (GB)
  • Papworth Hospital NHS Foundation Trust (GB)
Corresponding author
Marciniak, Stefan J.
Venue
British Journal of Cancer
Published
2021-07-05
Volume
125
Issue
8
Pages
1039-1055
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W3182664105
Cited by
31
References
228
Citations by year
2026: 3 · 2025: 2 · 2024: 5 · 2023: 6 · 2022: 13 · 2021: 2
FWCI
1.05
Type
journal article
Language
en
Open access
Licence
Locations
  • British Journal of Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo
Funders
  • British Lung Foundation
  • Royal Society through a University Research Fellowship and the Engineering and Physical Sciences Research Council
  • China Scholarship Council
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
  • Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
mesothelioma, asbestos exposure, tumor suppressor loss, epigenetic dysregulation, nutritional stress, immunotherapy, targeted therapy, cancer therapy development, tumor biology
MeSH terms
Asbestos, Combined Modality Therapy, Humans, Mesothelioma, Prognosis, Epigenesis, Genetic, Gene Regulatory Networks

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biological basis for novel mesothelioma therapies. https://app.cochat.ai/papers/10.1038/s41416-021-01462-2
The paper
Obacz, J., Yung, H., Shamseddin, M., Linnane, E., Liu, X., Azad, A. A., Rassl, D. M., Fairen-Jimenez, D., Rintoul, R. C., Nikolić, M. Z., & Marciniak, S. J. (2021). Biological basis for novel mesothelioma therapies. British Journal of Cancer. https://doi.org/10.1038/s41416-021-01462-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.